



Ref: FOIA Reference 2018/19-450

Date: 2<sup>nd</sup> November 2018

Tel: 01782 676474  
Email [FOI@uhn.nhs.uk](mailto:FOI@uhn.nhs.uk)

Dear

I am writing in response to your email dated 26<sup>th</sup> October 2018 requesting information under the Freedom of Information Act (2000) regarding cancer treatments.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

**Q1 In the past 3 months, how many mNSCLC patients were treated with?**

- Afatinib
- Atezolizumab
- Becacizumab
- Ceritinib
- Crizotinib
- Erlotinib
- Gefitinib
- Nitendaninb
- Nivolumab
- Pembrolizumab
- Pemetrexed
- Ramucirumab

A1 Please see below : ( the past 3 months: July 2018 to September 2018)

Afatinib	4
Atezolizumab	7
Bevacizumab	0
Ceritinib	1
Crizotinib	1
Erlotinib	2
Gefitinib	2
Nintedanib	9
Nivolumab	3
Pembrolizumab	29
Pemetrexed	31

Ramucirumab	0
-------------	---

**Q2 Metastatic hepatocellular carcinoma**

In the past three months, how many patients were treated with?

- Bevacizumab
- Cisplatin
- Doxorubicin
- Everolimus
- Lapatinib
- Lenvatinib
- Regorafenib
- Sorafenib
- Sunitinib
- TACE
- Other active systemic anti-cancer therapy

A2 Please see below:( past 3 months, July 2018 to September 2018)

Bevacizumab	0
Cisplatin	0
Doxorubicin	0
Everolimus	0
Lapatinib	0
Lenvatinib	0
Regorafenib	0
Sorafenib	0
Sunitinib	0
TACE	2
Other active systemic anti-cancer therapy	Nil

**Q3 Metastatic Thyroid Cancer**

In the past three months, how many patients were treated with?

- Axitinib
- Cabozantinib
- Lenvatinib
- Pazopanib
- Sorafenib
- Sunitinib
- Vandetanib
- Others

A3 Please see below:( past 3 months, July 2018 to September 2018)

Axitinib	0
Cabozantinib	0
Lenvatinib	2
Pazopanib	0
Sorafenib	0
Sunitinib	0
Vandetanib	1
Others	Nil

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,



Leah Carlisle  
**Deputy Head of Quality, Safety & Compliance**